Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors

  • Authors:
    • Guopei Luo
    • Kaizhou Jin
    • He Cheng
    • Chen Liu
    • Meng Guo
    • Yu Lu
    • Chao Yang
    • Jinzhi Xu
    • Wenquan Wang
    • Heli Gao
    • Shirong Zhang
    • Jiang Long
    • Jin Xu
    • Quanxing Ni
    • Jie Chen
    • Xianjun Yu
  • View Affiliations

  • Published online on: September 26, 2017     https://doi.org/10.3892/ol.2017.7071
  • Pages:6795-6800
0

Abstract

Carbohydrate antigen 19‑9 (CA19‑9) is not generally considered to be a biomarker in pancreatic neuroendocrine tumors (pNETs), as the majority of pNETs present with a normal range of CA19‑9. The present study aimed to evaluate the role of serum CA19‑9 levels as a prognostic factor in a relatively large number of patients with pNETs. Consecutive patients were retrospectively collected from a single institution between June 2006 and February 2015. The receiver operating characteristic (ROC) curve and the area under the ROC curve were used to select the cut‑off values for the baseline CA19‑9 levels. The primary end point was set as overall survival. Potential factors associated with the abnormal elevation of CA19‑9 expression levels in pNETs were also investigated. The cut‑off value for CA19‑9 was 16 U/ml as determined by the ROC curve, and for the area under the ROC curve it was 0.68. In total, 32.7% of patients (51/156) had CA19‑9 expression levels higher than the cut‑off value. Univariate analysis demonstrated that CA19‑9 >16 U/ml was an adverse prognostic factor for patients' overall survival. The CA19‑9 >16 U/ml group had a statistically higher proportion of tumor node metastasis (TNM) stage III or IV, as compared with the CA19‑9 ≤16 U/ml group. To the best of our knowledge, the present study is the first to demonstrate that CA19‑9 is a prognostic biomarker of pNETs, one that may reflect its aggressiveness and severity.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Luo, G., Jin, K., Cheng, H., Liu, C., Guo, M., Lu, Y. ... Yu, X. (2017). Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncology Letters, 14, 6795-6800. https://doi.org/10.3892/ol.2017.7071
MLA
Luo, G., Jin, K., Cheng, H., Liu, C., Guo, M., Lu, Y., Yang, C., Xu, J., Wang, W., Gao, H., Zhang, S., Long, J., Xu, J., Ni, Q., Chen, J., Yu, X."Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors". Oncology Letters 14.6 (2017): 6795-6800.
Chicago
Luo, G., Jin, K., Cheng, H., Liu, C., Guo, M., Lu, Y., Yang, C., Xu, J., Wang, W., Gao, H., Zhang, S., Long, J., Xu, J., Ni, Q., Chen, J., Yu, X."Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors". Oncology Letters 14, no. 6 (2017): 6795-6800. https://doi.org/10.3892/ol.2017.7071